1. Pink Sheet
  2. >>Market Access

Colombian Crack Down On Compulsory Licensing Under Attack

 
• By Francesca Bruce

Civil society groups are calling for Colombian authorities to repeal a controversial decree that they say will make compulsory licensing harder and which would prevent declarations of public interest from being used to lower drug prices.

Colombia
Colombian NGOs Fight For Compulsory Licensing • Source: Shutterstock

Civil society groups in Colombia have signed a letter calling for the Colombian government to repeal a decree that they say stifles compulsory licensing and prevents declarations of interest (DPIs) from being used to control medicine prices. According to the groups, the decree, published by the ministry of commerce, is to punish the health ministry for slashing the price of Novartis AG‘s cancer drug Glivec (imatinib) after declaring it to be of public interest.

The ministry of commerce published decree 670 of 2017 in April. The decree changes the procedures for declaring the existence of reasons for why a product may be of public...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By Lisa Takagi

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.

GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals?

 
• By Cathy Kelly

For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.

Rocky Rollout Spells Trouble for Medicare Prescription Payment Plan

 
• By Lauren Flynn Kelly

Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.

PBM Investigation, Enforcement Action ‘Critical Priorities’ At FTC, Chair Says

 
• By Cathy Kelly

The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.

More from Pink Sheet

EMA Official Clarifies Benefits And Limitations Of Innovation Pathways

 
• By Eliza Slawther

A European Medicines Agency official provided an overview and update of the support the EMA offers developers of innovative products and discussed, among other things, its Innovation Task Force, Quality Innovation Group and a scientific advice pilot for clinical trials.

EU Emergency Response Authority Needs Bigger Budget To Address Health Threats, Says Industry

 
• By Eliza Slawther

The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.